Actively Recruiting
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
Led by Centre Georges Francois Leclerc · Updated on 2023-10-17
150
Participants Needed
2
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.
CONDITIONS
Official Title
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Woman aged between 18 and 85
- Histologically proven infiltrating breast cancer
- Breast cancer is triple negative or hormone receptor positive/HER2 negative as defined
- Receiving treatment in one of these cohorts: metastatic with Paclitaxel, metastatic with Epirubicin-cyclophosphamide, metastatic with Eribulin, or first-line metastatic with Palbociclib, Abemaciclib, or Ribociclib combined with hormone therapy
- Signed informed consent for the study
- Fit and able to follow the protocol including visits, specimen collection, and follow-up
- Affiliated with the social security system
You will not qualify if you...
- Unable to understand, read, or sign informed consent
- Presence of cerebral or meningeal metastasis
- Use of immunosuppressive drugs within 14 days before inclusion, except certain corticosteroids
- Participation in another research that may alter systemic treatment within the cohort
- Pregnant or breastfeeding
- Positive for HIV, HBV, or HCV serology
- Life expectancy less than 3 months
- Refusal to participate
- Under adult protection systems such as tutorship or curatorship
- Unable to undergo medical monitoring due to geographical, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHRU Jean Minjoz
Besançon, France, 25000
Not Yet Recruiting
2
Centre Georges Francois Leclerc
Dijon, France, 21079
Actively Recruiting
Research Team
S
Sylvain LADOIRE, PU-PH
CONTACT
E
Emilie REDERSTORFF
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here